Crinetics Pharma Officer Plans $217K Stock Sale via 10b5-1 Plan
Crinetics Pharmaceuticals, Inc.
Subscribe to track CRNX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Crinetics Pharma Officer Plans $217K Stock Sale via 10b5-1 Plan
Company: Crinetics Pharmaceuticals, Inc. (CRNX) Form: 144 | Filed: 2025-11-03 Significance: Low
Insider: Dana Pizzuti Title: Officer
Transaction: • Type: Proposed Sale • Shares: 5,000 • Price: ~$43.50 • Value: $217,500
Key Insight: An officer has filed a notice of a proposed sale representing a negligible fraction (0.0053%) of the company's market cap. The transaction is pre-scheduled under a 10b5-1 plan.
Market Context: This is a routine sale for personal financial management, not indicative of a change in the insider's outlook on the company. The small size relative to the company's $4.1B market cap suggests no market impact is expected.
Comprehensive Analysis
SEC Filing Analysis: Crinetics Pharmaceuticals, Inc. (CRNX)
Executive Summary
- Trading Significance: Low
- Key Takeaway: An officer of Crinetics Pharmaceuticals has filed a notice of a proposed sale of 5,000 shares, valued at approximately $217,500. The sale is pre-arranged under a 10b5-1 plan, indicating it is for personal financial planning.
- Market Impact: The transaction is negligible in size and is not expected to have any impact on the stock's price or trading volume.
Company Information
| Field | Value |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. |
| Ticker Symbol | CRNX |
| CIK | 0001658247 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Dana Pizzuti |
| CIK | 0001948238 |
| Title/Position | Officer |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 |
| Transaction Date | 2025-11-03 |
| Transaction Code | null |
| Security Type | Common Stock |
| Shares Involved | 5,000 |
| Price Per Share | $43.50 |
| Total Value | $217,500 |
| Shares Owned After | null |
| Ownership Type | null |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $217,500 |
| % of Market Cap | 0.0053% |
| Shares Transacted | 5,000 |
| % of Shares Outstanding | 0.0053% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The proposed sale of $217,500 is insignificant for a company with a market capitalization of $4.1 billion.
- Transaction Significance: The transaction represents a minuscule percentage of both the company's market value and its total shares outstanding, classifying it as a routine, non-material event.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The small size of the transaction and its execution under a pre-disclosed 10b5-1 trading plan remove any speculative element. Such sales are common for executive compensation and diversification.
Volume & Sentiment
- Expected Volume Impact: Negligible. The 5,000 shares are unlikely to be noticeable in the stock's daily trading volume.
- Sentiment Indicator: Neutral. The market generally does not react to small, pre-planned insider sales.
Additional Context
Transaction Notes
- Special Circumstances: This proposed sale is pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. The filing also discloses a pattern of similar small sales in the preceding months, reinforcing the routine nature of this activity.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.